Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyvox Phase IV Studies May Support Penicillin-Resistant Indications

Executive Summary

Pharmacia will continue to seek additional indications for Zyvox (linezolid) in the treatment of antibiotic-resistant infections.

You may also be interested in...



Dalvance: First QIDP Antibiotic Breaks New Regulatory Ground; Label Doesn’t

Durata has post-marketing requirements to continue resistance-related studies, but its label includes stewardship language similar to other antibiotics.

FDA Wants Promotional “Targets” From Sponsors Throughout Drug Development

Sponsors should provide FDA with proposed promotional claims at the beginning of the drug development process, the agency said in a draft guidance

FDA Wants Promotional “Targets” From Sponsors Throughout Drug Development

Sponsors should provide FDA with proposed promotional claims at the beginning of the drug development process, the agency said in a draft guidance

Related Content

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel